Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Roche and Synosis have formed a new partnership that could lead to the development of five different treatments for schizophrenia, cognitive disorders, Parkinson's disease, drug dependency and pain.
Subscribe to our email newsletter
The broad partnership centers on five drug candidates that Synosis will acquire from Roche, including four phase I molecules, which target the central nervous system. Roche had discontinued the development of these compounds in previous reprioritization processes.
“Unlike the traditional licensing model, this deal shows how venture capitalists and pharma can build partnerships based on a whole portfolio of promising clinical-stage drug candidates,” said Brad Bolzon, managing director of Versant Ventures.
Under the terms of the deal, Synosis will be responsible for the clinical development and, in some cases, commercialization of the drug candidates in multiple indications. Financial terms of the deal were not disclosed.